Guizhou Xinbang Pharmaceutical Co., Ltd.

SZSE:002390 Lagerbericht

Marktkapitalisierung: CN¥6.7b

Guizhou Xinbang Pharmaceutical Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Guizhou Xinbang Pharmaceutical has been growing earnings at an average annual rate of 32.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 0.4% per year. Guizhou Xinbang Pharmaceutical's return on equity is 4%, and it has net margins of 3.5%.

Wichtige Informationen

32.8%

Wachstumsrate der Gewinne

30.4%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie10.9%
Wachstumsrate der Einnahmen0.4%
Eigenkapitalrendite4.0%
Netto-Marge3.5%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Sep 26
There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings

Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

Jun 26
Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

May 24
These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

Aufschlüsselung der Einnahmen und Ausgaben

Wie Guizhou Xinbang Pharmaceutical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

SZSE:002390 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 246,2032177406
30 Jun 246,2512467645
31 Mar 246,4382937845
31 Dec 236,4612878035
30 Sep 236,4872308163
30 Jun 236,4632498263
31 Mar 236,3772048592
01 Jan 236,3502248551
30 Sep 226,4353048132
30 Jun 226,5172528271
31 Mar 226,5902748022
01 Jan 226,4722737932
30 Sep 216,2892608221
30 Jun 216,2412908062
31 Mar 216,0602597873
31 Dec 205,84617481311
30 Sep 205,91615982923
30 Jun 206,08015187230
31 Mar 206,33916193232
31 Dec 196,65523692537
30 Sep 196,573-1,36096338
30 Jun 196,584-1,37192636
31 Mar 196,630-1,30892441
31 Dec 186,580-1,29791837
30 Sep 186,65133783430
30 Jun 186,52736881547
31 Mar 186,16034173138
31 Dec 176,00231970830
30 Sep 175,80029380022
30 Jun 175,4372637920
31 Mar 175,3502557930
31 Dec 165,1572467560
30 Sep 165,0442436680
30 Jun 164,8642236240
31 Mar 164,4881855930
31 Dec 154,1801745400
30 Sep 153,7881894620
30 Jun 153,4771804400
31 Mar 153,2171724200
31 Dec 142,4761453890
30 Sep 141,7321003650
30 Jun 141,113693430
31 Mar 14572393010
31 Dec 13569403010

Qualität der Erträge: 002390 has high quality earnings.

Wachsende Gewinnspanne: 002390's current net profit margins (3.5%) are lower than last year (3.5%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 002390 has become profitable over the past 5 years, growing earnings by 32.8% per year.

Beschleunigtes Wachstum: 002390's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Erträge im Vergleich zur Industrie: 002390 had negative earnings growth (-5.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).

Eigenkapitalrendite

Hohe Eigenkapitalrendite: 002390's Return on Equity (4%) is considered low.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y